Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Exemestane versus Continued Tamoxifen after 2-3 Years of Tamoxifen in Early Breast Cancer
ACTRN12607000033448Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 1998
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in breast cancer comparing Exemestane switch arm with Continued tamoxifen arm (2 arms). Primary endpoint: Disease-free survival. Started Aug 1998; status: completed.
02
Drugs
exemestanetamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12607000033448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000033448.